These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 9349632

  • 1. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat.
    Bertolino F, Valentin JP, Patoiseau JF, Rieu JP, Colpaert FC, John GW.
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):462-6. PubMed ID: 9349632
    [Abstract] [Full Text] [Related]

  • 2. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F, Valentin JP, Maffre M, Grelac F, Bessac AM, Maclouf J, Delhon A, Lévy-Toledano S, Patoiseau JF, Colpaert FC.
    Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
    [Abstract] [Full Text] [Related]

  • 3. Analysis of the pulmonary hypertensive effects of the isoprostane derivative, 8-iso-PGF2alpha, in the rat.
    John GW, Valentin JP.
    Br J Pharmacol; 1997 Nov; 122(5):899-905. PubMed ID: 9384506
    [Abstract] [Full Text] [Related]

  • 4. Nitric oxide regulation of TP receptor-mediated pulmonary vasoconstriction in the anesthetized, open-chest rat.
    Valentin JP, Bessac AM, Maffre M, John GW.
    Eur J Pharmacol; 1996 Dec 19; 317(2-3):335-42. PubMed ID: 8997619
    [Abstract] [Full Text] [Related]

  • 5. Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.
    Valentin JP, Jover B, Maffre M, Bertolino F, Bessac AM, John GW.
    Am J Hypertens; 1997 Sep 19; 10(9 Pt 1):1058-63. PubMed ID: 9324114
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
    Krauss AH, Woodward DF, Burk RM, Gac TS, Gibson LL, Protzman CE, Abbass F, Marshall K, Senior J.
    J Ocul Pharmacol Ther; 1997 Aug 19; 13(4):303-12. PubMed ID: 9261766
    [Abstract] [Full Text] [Related]

  • 10. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
    Karasawa A, Shirakura S, Higo K, Kubo K.
    Arzneimittelforschung; 1991 Dec 19; 41(12):1237-41. PubMed ID: 1815522
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
    Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW.
    J Pharmacol Exp Ther; 1994 Feb 19; 268(2):747-52. PubMed ID: 8113986
    [Abstract] [Full Text] [Related]

  • 13. Antagonism of thromboxane actions in the isolated perfused rat heart.
    Stahl GL, Darius H, Lefer AM.
    Life Sci; 1986 Jun 02; 38(22):2037-41. PubMed ID: 2940431
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate.
    Pestel S, Nath A, Jungermann K, Schieferdecker HL.
    Biochem Pharmacol; 2003 Aug 15; 66(4):643-52. PubMed ID: 12906929
    [Abstract] [Full Text] [Related]

  • 16. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S, Karasawa A, Kubo K.
    Arzneimittelforschung; 1991 Dec 15; 41(12):1242-5. PubMed ID: 1815523
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Thromboxane A2 contributes to the enhanced tubuloglomerular feedback activity in young SHR.
    Brännström K, Arendshorst WJ.
    Am J Physiol; 1999 May 15; 276(5):F758-66. PubMed ID: 10330058
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov 15; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.